Cosciens Biopharma (TSX:CSCI) Cyclically Adjusted Book per Share: C$14.22 (As of Mar. 2026)


TSX:CSCI Cosciens Biopharma Inc TSX:CSCI
50 GF Score
Price C$3.66
GF Value C$3.31
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Cosciens Biopharma Cyclically Adjusted Book per Share?

Cosciens Biopharma TSX:CSCI +223.15% 50 Cyclically Adjusted Book per Share is C$14.22 as of Mar. 2026. GuruFocus rates TSX:CSCI with a GF Score™ of 50/100 and a GF Value™ of C$3.31 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cosciens Biopharma's adjusted book value per share for the three months ended in Mar. 2026 was C$19.810. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$14.22 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Cosciens Biopharma's average Cyclically Adjusted Book Growth Rate was 0.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 9.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 16.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 36.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Cosciens Biopharma was 150.00% per year. The lowest was 9.50% per year. And the median was 47.95% per year.

As of today (2026-07-03), Cosciens Biopharma's current stock price is C$3.66. Cosciens Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was C$14.22. Cosciens Biopharma's Cyclically Adjusted PB Ratio of today is 0.26.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cosciens Biopharma was 132.34. The lowest was 0.08. And the median was 3.06.


Cosciens Biopharma  (TSX:CSCI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cosciens Biopharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.66/14.22
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cosciens Biopharma was 132.34. The lowest was 0.08. And the median was 3.06.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cosciens Biopharma Cyclically Adjusted Book per Share Related Terms


Cosciens Biopharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Cyclically Adjusted Book per Share Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.51 10.72 12.71 13.83 14.06

Cosciens Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.09 14.18 14.18 14.06 14.22

TSX:CSCI vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Cyclically Adjusted PB Ratio falls into.


TSX:CSCI
50GF Score
Cosciens Biopharma Inc TSX:CSCI
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cosciens Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=19.81/132.2600*132.2600
=19.810

Current CPI (Mar. 2026) = 132.2600.

Cosciens Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 21.867 102.002 28.354
201609 36.392 101.765 47.297
201612 37.744 101.449 49.207
201703 39.236 102.634 50.562
201706 40.809 103.029 52.387
201709 40.167 103.345 51.406
201712 38.539 103.345 49.322
201803 37.695 105.004 47.480
201806 37.364 105.557 46.816
201809 37.812 105.636 47.342
201812 37.789 105.399 47.420
201903 37.474 106.979 46.330
201906 36.997 107.690 45.438
201909 36.388 107.611 44.723
201912 36.997 107.769 45.405
202003 37.912 107.927 46.459
202006 39.989 108.401 48.790
202009 40.170 108.164 49.119
202012 39.966 108.559 48.691
202103 40.499 110.298 48.563
202106 41.187 111.720 48.759
202109 42.951 112.905 50.314
202112 45.545 113.774 52.945
202203 48.476 117.646 54.498
202206 50.098 120.806 54.848
202209 50.538 120.648 55.402
202212 52.553 120.964 57.461
202303 52.617 122.702 56.716
202306 50.362 124.203 53.629
202309 48.419 125.230 51.137
202312 45.813 125.072 48.446
202403 42.258 126.258 44.267
202406 35.205 127.522 36.513
202409 26.043 127.285 27.061
202412 17.908 127.364 18.596
202503 13.883 129.181 14.214
202506 9.168 129.892 9.335
202509 6.624 130.290 6.724
202512 4.995 130.370 5.067
202603 19.810 132.260 19.810

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of C$14.22 mean?
Cosciens Biopharma (TSX:CSCI) has a Cyclically Adjusted Book per Share of C$14.22 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Cyclically Adjusted Book per Share too high?
Cosciens Biopharma's current Cyclically Adjusted Book per Share is C$14.22. Overall, Cosciens Biopharma has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Cosciens Biopharma's Cyclically Adjusted Book per Share of C$14.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Cyclically Adjusted Book per Share is C$14.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (TSX:CSCI) is currently considered Significantly Overvalued. The stock's GF Value™ is C$3.31, compared to a current price of C$3.66 — trading 10.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is C$14.22. Cosciens Biopharma's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Cosciens Biopharma (TSX:CSCI), the current Cyclically Adjusted Book per Share is C$14.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (TSX:CSCI) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued. The current stock price of C$3.66 is trading 10.6% above its estimated GF Value™ of C$3.31. GuruFocus considers Cosciens Biopharma to be Significantly Overvalued.

Key valuation signals for TSX:CSCI:

  • Cyclically Adjusted Book per Share: C$14.22
  • GF Value™: C$3.31 vs. price of C$3.66 (10.6% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the TSX:CSCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cosciens Biopharma Business Description

Other Exchanges CSCIF:USAET8:Germany
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
50GF Score

Get the complete analysis for TSX:CSCI

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$3.66
Price
C$3.31
GF Value